BRAF and melanoma: For example, dual BRAF/MEK inhibition induces cleavage of pyroptosis marker gasdermin E (GSDME) and intra-tumoral T cell infiltration, but BRAFi/MEKi resistance attenuates these responses in melanoma [48].